Abstract
Objective. Assignment of clinic-economical analysis of priority drug units by additional methods which are highturnover
products and characterized by high costs and proven efficiency.
Material and methods. Content-analysis of database allowed to distinguish 88 trademarks of drugs with
different doses and forms of administration which were used in department of neonatal surgery for congenital
heart diseases between 01.01.2011 and 31.12.2011. Drugs in use were ranged according to ABC-
analysis in decreasing order into three groups: "A" - the most cost-based drugs (80% of budget), "B" - less
cost-based drugs (15% of budget), "C" - the least cost-based drugs (5% of budget). Drugs were distributed
within each group according to the predictability degree of their expendityre. XYZ-analysis evaluated the
significance of drugs depending on the rate of use. VEN-analysis was performed using formal and expert
approaches.
Results. ABC-analysis showed that 79.4% of total expenditure accrued to 13 drugs (11.8% of total number) from
group "A". Group "B" included 29 drugs (23.5%), which composed 15.5% of drug budget. Group "C" included 46
(64.7%) drugs which composed 5.1% of budget. VEN-analysis showed that 69 drugs (78.4%) were included in
group "V" and composed 62.4% of expense structure. 37.6% of total expenditure were spent on drugs of "N" group.
Drugs requiring special attention were distributed into groups "AE", "BE" and "BN" of ABC-VEN integrated matrix.
ABC-XYZ analysis of medicinal stock revealed that 73.9% of items from drug list are characterized by irregular use
because of absence in stable demand and regular use (drugs of "Z" group). 14.8% of drugs are characterized by
mean stability of usage (group "Y) and only 11.3% of items in drug list for congenital heart disease treatment have
a strong demand (group "X).
Conclusion. Integrated ABC-VEN matrices increase the efficiency of management in medical resources,
allow to reduce the share of high-cost drugs without disturbance of assortment policy principles and to
detect crucial drugs and causes which influence on their amount. We can recommend to purchase the drugs
of "X" group according to planned requirements, synchronous application in treatment process. Drugs of "Y"
group can be stored and drugs of "Z" group can be purchased on demand. The obtained data show the expediency
of changing the structure of purchasing the drugs and increasing the share of essential and necessary
drugs.
References
Алексеев, Н. А. Оптимизация лекарственного обеспечения в многопрофильной больнице на основе фармакоэкономического анализа / Н. А. Алексеев, М. Н. Алексеев // Экономика здравоохранения. - 2007. - № 1. - С. 42-45.
Бешелев, С. Д. Математико-статистические методы экспертных оценок / С.Д. Бешелев, Ф.Г. Гурвич. - 2-е изд. перераб. и доп. - М.: Статистика, 2000. - 263 с.
Буйлин, А. ABC-XYZ-анализ ассортимента выпускаемой продукции как элемент стратегического маркетинга / А. Буйлин // Ремедиум. - 2005. - № 3. - С. 80-84.
Воробьев, П. А. АВС-, VEN- и частотный анализы в здравоохранении / П. А. Воробьев // Проблемы стандартизации в здравоохранении. - 2004. - № 3. - С. 8-11.
Воробьев П. А. Клинико-экономический анализ / П. А. Воробьев. - М.: Ньюдиамед, 2008. - 364 с.
Гиляревский, С. Р. Современные принципы анализа экономической эффективности медицинских вмешательств / С. Р. Гиляревский // Экономика здравоохранения. - 2001. - № 9. - С. 8-11.
